ABSTRACT
Objective@#To study the urinary iodine level of pregnant women with thyroid disease in Shenzhen, and to provide scientific basis for rational iodine supplementation.@*Methods@#A total of 170 pregnant women with thyroid diseases who visited Department of Endocrinology, Peking University Shenzhen Hospital from January 2017 to March 2019 were selected as the subjects, they were divided into hyperthyroidism group (84 cases) and non-hyperthyroidism group (86 cases) according to whether they had hyperthyroidism or not. Morning urine sample was collected under normal dietary conditions; urinary iodine was detected by peroxyacetic acid tetramethylbenzidine oxidation colorimetry. Urinary iodine < 150 μg/L was iodine deficiency and 150-249 μg/L was appropriate iodine.@*Results@#The median of urinary iodine of pregnant women with thyroid disease in Shenzhen was 143.9 μg/L, which was slightly lower than the lowest limit of the appropriate iodine level. The median of urinary iodine in hyperthyroidism group was 116.6 μg/L, which was at the iodine deficiency level; the median of urinary iodine in non-hyperthyroidism group was 181.6 μg/L, which was at the appropriate iodine level. There was significant difference in urinary iodine levels between hyperthyroidism group and non-hyperthyroidism group (Z =-2.261, P < 0.05).@*Conclusion@#The urinary iodine of pregnant women with hyperthyroidism in Shenzhen is slightly low.
ABSTRACT
Objective To study the urinary iodine level of pregnant women with thyroid disease in Shenzhen, and to provide scientific basis for rational iodine supplementation. Methods A total of 170 pregnant women with thyroid diseases who visited Department of Endocrinology, Peking University Shenzhen Hospital from January 2017 to March 2019 were selected as the subjects, they were divided into hyperthyroidism group (84 cases) and non-hyperthyroidism group (86 cases) according to whether they had hyperthyroidism or not. Morning urine sample was collected under normal dietary conditions; urinary iodine was detected by peroxyacetic acid tetramethylbenzidine oxidation colorimetry. Urinary iodine < 150 μg/L was iodine deficiency and 150 - 249 μg/L was appropriate iodine. Results The median of urinary iodine of pregnant women with thyroid disease in Shenzhen was 143.9 μg/L, which was slightly lower than the lowest limit of the appropriate iodine level. The median of urinary iodine in hyperthyroidism group was 116.6 μg/L, which was at the iodine deficiency level; the median of urinary iodine in non -hyperthyroidism group was 181.6 μg/L , which was at the appropriate iodine level. There was significant difference in urinary iodine levels between hyperthyroidism group and non-hyperthyroidism group (Z =- 2.261, P < 0.05). Conclusion The urinary iodine of pregnant women with hyperthyroidism in Shenzhen is slightly low.
ABSTRACT
Objective To study the expressions of the tumor suppressor gene TSH receptor( TSHR),P16, and RAS in papillary thyroid carcinoma ( PTC ) , and the correlation between the occurrence of tumor and the aberrant promoter hypermethylation of three tumor suppressor genes. Methods RT-PCR was used to detect the mRNA expression of three tumor suppressor genes in tissues of 50 cases of PTC ,20 cases of nodular goiter,and 12 cases of thyroid adenoma. The promoter methylation status of three tumor suppressor genes was examined by methylation-specific PCR technique( MSP). Gene sequencing was used to test if the hypermethylation existed in the promoter of three tumor suppressor genes. Results In 68.0% (34/50) TSHR gene, 54.0% (27/50) P16 gene, and 60.0% ( 30/50 ) RAS gene in PTCs, hypermethylation in promoter region was detected, the respective results 21.9% (7/32) , 15. 6% (5/32) ,and 31. 3% (10/32) were found in control tissues. The rates of the three genes with promoter hypermethylation in PTC were significantly higher than those in control tissues ( all P<0. 05). The mRNA expressions of TSHR,P16,and RAS were significantly lower in PTC than those in control tissues (0. 41 ± 0.11 vs 0.63±0. 08,0. 51±0. 17 vs 0. 72±0. 22,0. 56±0. 10 vs 0. 67±0. 16, all P<0. 05). The sequencing confirmed that there was CC to TC transmission in the promoters of three tumor suppressor genes. Conclusions The methylation of three tumor suppressor genes in promoter region is a common molecule event and may be involved in the genesis and development of human PTC.
ABSTRACT
The alterations in atherogenic index of plasma (AlP) in type 2 diabetic patients and their normoglycemic first-degree relatives (NFDR) were investigated, and the effects of Acarbose or Glimepiride on AIP in 99 type 2 diabetic patients were evaluated. Triglycerride (TG), total cholesterol, high density lipoprotein-cholesterol (HDL-C) levels were analyzed, and Log (TG/HDL-C) was calculated as AIP in 62 type 2 diabetic patients and their 67 NFDR from 29 type 2 diabetic pedigrees and in 45 healthy controls without family histories of diabetes. Also analyzed were the same parameters in 99 type 2 diabetic patients before and after therapy with Acarbose or Glimepiride. The results revealed that diabetic patients and their NFDR had significantly higher AIP than did the controls, whereas no significant differences were seen between diabetic patients and their NFDR. Positive correlation of AIP between type 2 diabetic patients and their offspring were observed (r = 0.241, P < 0.05). After 8 weeks therapy with Acarbose, the AIP of type 2 diabetic patients was decreased significantly, and no differences were observed for AIP levels in Glimepiride group although the AIP was lower when compared with the untreated level. As a significant inverse correlation of small dense low density lipoprotein (sdLDL) with AIP was confirmed, our data suggest that diabetic patients and their NFDR from type 2 diabetic pedigrees had significantly higher AIP than did controls; AIP could be decreased by therapy with Acarbose in type 2 diabetic patients; Glimepiride may bring potential benefit to type 2 diabetic patients by influencing sdLDL.
Subject(s)
Humans , Acarbose , Therapeutic Uses , Atherosclerosis , Blood , Body Mass Index , Case-Control Studies , Cholesterol, HDL , Blood , Diabetes Mellitus, Type 2 , Blood , Drug Therapy , Hypoglycemic Agents , Therapeutic Uses , Pedigree , Sulfonylurea Compounds , Therapeutic Uses , Triglycerides , BloodABSTRACT
Objective To investigate the clinical significance of changes in lipids and apolipoproteins (Apo) in type 2 diabetic patients and their normoglycemic first-degree relatives (NFDR). Methods Triglyceride (TG), total cholesterol (TC), high density lipoprotein cholesterol (HDL-C), ApoAⅠ, ApoB_ 100 , ApoCⅢ and ApoE were determined in 62 type 2 diabetic patients and 67 NFDR from 29 Chinese type 2 diabetic pedigrees as well as 45 normoglycemic controls without family history of diabetes (NC) in Chengdu city, China. Results (1)TG level was higher in type 2 diabetic patients 〔(1.85?1.31)mmol/L〕 as compared with those in NFDR 〔(1.39?0.91)mmol/L〕 and NC 〔(0.92?0.45)mmol/L〕, and TG level in NFDR was higher as compared with that in NC (all P